Adam Brufsky, MD, PhD
Medical Director, Magee-Womens Cancer Program at the UPMC Hillman Cancer Center, Pittsburgh, PA, USA
View the Draft Meeting Agenda
Download a copy of the draft agenda and start discovering the discussion topics of the virtual meeting.
In May 2020, Aptitude Health will conduct a series of 3 online breast cancer expert forums focused on advances in HER2+ early stage breast cancer and current standards of care. The sessions will be chaired by Adam Brufsky, MD, PhD, Magee-Womens Cancer Program at the UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Life science partners have the ability to silently observe these important and timely online faculty discussions and to receive a comprehensive summary report including customized content specific to their products and areas of expertise.
Key Discussion Topics
- New Standards of Care in HER2+ Early Stage Breast Cancer
- Maximizing Patient Outcomes in HER2+ MBC
- Current and Investigational Approaches in Triple-Negative Breast Cancer
- Evolving Treatments and New Developments in HR+ Metastatic Breast Cancer
- Clinical Management of HR+ Early Stage Breast Cancer
3 Virtual Interactive Sessions
Day 1 | EPICS Advisory Board Session 1
The faculty consisting of top breast cancer experts will share their views via a 3-hour interactive virtual discussion on the newest clinical data, current treatment approaches, and their vision for how the landscape is likely to change in the future. Each clinical data presentation will be followed by a moderated discussion. During this first EPICS session, all stages of HER2+ breast cancer will be discussed.
Day 2 | EPICS Advisory Board Session 2
The clinical expert faculty will share their views during a 3-hour virtual discussion on the newest clinical data and treatment evolutions specific to hormone-receptor positive and triple-negative disease. Each presentation on the latest clinical data will be followed by a moderated discussion and recommendations from the group regarding current approaches in this patient population.
Day 3 | OncoBoard Discussion Platform Session 3
As a follow-up to the 2 expert advisory sessions, a select group of faculty members will revisit some of the key topics related to current treatment paradigms and controversies in breast cancer via the OncoBoard platform. OncoBoard provides life science companies a closed collaborative online platform for rapid answers to follow-up questions coming out of the first 2 sessions. A selection of topics will be proposed to the experts for discussion on the platform.
Click here to download the draft meeting agenda for a full overview of the topics covered in the live meetings and follow-up report series as well as to confirm your participation in these 3 sessions.
Jame Abraham, MD
Cleveland Clinic, Cleveland, OH, USA
Peter Kaufman, MD
University of Vermont Cancer Center, Burlington, VT, USA
Mark Pegram, MD
Stanford Cancer Institute,
Stanford, CA, USA
William J. Gradishar, MD, FASCO, FACP
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
Virginia Kaklamani, MD, DSc
UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA
Jasgit C. Sachdev, MD
Translational Genomics Research Institute, Scottsdale, AZ, USA
Monica Fornier, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Rita Nanda, MD
University of Chicago Hematology Oncology, Chicago, IL, USA
Hope Rugo, MD
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA